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Invited paper: 
 
THE INTRA-AORTIC BALLOON PUMP IN HEART FAILURE MANAGEMENT: 
IMPLICATIONS FOR NURSING PRACTICE 
Abstract  
Management of acute heart failure is an important consideration in critical care. 
Mechanical support of the failing heart is crucial for improving health outcomes. 
The most common Australasian application of intraaortic balloon 
counterpulsation (IABP)  is in the setting of cardiogenic shock. High end users 
of IABP (>37/annum) demonstrate significantly lower mortality for cardiogenic 
shock managed with IABP (p <0.001) in contrast to hospitals which employ 
limited IABP (<4/annum). This underscores the importance of proficiency in 
managing patient receiving IABP support. Nurses play a crucial role in carding 
for patients with acute heart failure. This paper summarises care considerations 
for management of the IABP.
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Introduction 
Management of acute heart failure is an important consideration in critical care 
units. Following the initial application to practice in 1968, intraaortic balloon 
counterpulsation (IABP) has become the most widely used mechanical support 
in the assistance of the failing heart. Australasian application of IABP is most 
predominant in the setting of cardiogenic shock.1 Of interest, high end users of 
IABP (>37/annum) demonstrate significantly lower mortality for cardiogenic 
shock managed with IABP (p <0.001) in contrast to hospitals which employ 
limited IABP (<4/annum). High volume facilities experience up to 150 fewer 
deaths per 1000 IABP recipients.2 This marked reduction in mortality suggests 
IABP knowledge and modality proficiency to contribute toward improved IABP 
outcome.3 Nurses play a crucial role in caring for people receiving IABP 
therapy.  This paper describes the implications for nursing practice which result 
from IABP insertion, management and weaning from the device. 
Nurses who care for patients managed with IABP require a knowledge of the 
mechanisms and actions of this therapeutic device. As well as addressing IABP 
physiology, benefits, potential complications and safety considerations, this 
paper discusses the importance of monitoring cardiac function and undertaking 
regular comprehensive patient assessment – core nursing responsibilities in the 
management of IABP. How assessment must be informed by an understanding 
of IABP complications and safety issues will be addressed, as will IABP timing 
and how this can maximise impaired cardiac function. Finally, discussion will 
describe patients ready to be weaned from IABP with consideration given to 
understanding weaning strategies and their implications for nursing practice.  
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Physiologic effects of intraaortic balloon counterpulsation  
The principal characteristic of acute heart failure is inadequate contractile force 
of the myocardium resulting in a failure to maintain adequate cardiac output.4 
This reduction in contractility is a product of inadequate myocardial oxygenation 
and increasing cardiac workload. The primary purpose of IABP is the support of 
the failing heart by simultaneously increasing myocardial oxygen supply and 
decreasing myocardial oxygen demand.5 This is achieved by the positioning of 
an intra-aortic balloon (IAB) in the descending thoracic aorta. The IAB is located 
immediately inferior to the origin of the left subclavian artery and superior to the 
renal arteries and is attached to an external drive console which inflates and 
deflates the IAB in synchrony with cardiac contractions.5 The IAB is inflated at 
the onset of diastole when blood ceases to eject from the heart. It displaces 
blood volume within the descending thoracic aorta. Proximal blood is returned 
to the heart to oxygenate the coronary arteries as well as being distributed 
through the branches in the aortic arch. Blood in the distal descending aorta is 
circulated systemically.6  Balloon deflation is timed to occur immediately prior to 
the onset of systole before the heart commences ejection. Balloon deflation 
leaves the aorta partially empty thus reducing afterload, maximising left 
ventricular ejection fraction and reducing mitral regurgitation. By augmenting 
coronary artery and systemic perfusion pressures, IABP improves myocardial 
oxygen supply and decreases myocardial oxygen consumption by reducing 
cardiac workload.5, 7 Understanding these physiological effects enables the 
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nurse to effectively manage patients treated with IABP with a specific focus on 
expected improvements in cardiac function.  
 
Intraaortic balloon counterpulsation timing 
To optimise cardiac function in the setting of IABP inflation of the IAB must be 
synchronised with the cardiac cycle. Timing of IAB inflation and deflation is 
achieved by choosing a trigger which accurately predicts the open and closure 
of the aortic valve. The preferred trigger is the electrocardiogram (ECG) tracing. 
Other triggers such as aortic pressure or pacing spikes may be used if 
necessary.8 The ECG is the favoured trigger as the R wave provides the most 
accurate reference point for signalling the onset of ventricular systole and the 
opening of the aortic valve.5 Even in the context of irregular and paced rhythms 
the R wave will offer the clearest indication of the onset of systole. The 
importance of a reliable trigger for balloon inflation and deflation is crucial for 
optimised IABP.8-10 Ideally ECG monitoring leads are attached directly to the 
IABP drive console. However, an option exists for the drive console to ‘slave’ 
the ECG trace from the cardiac monitor – as such, It is not unusual for a patient 
managed with IABP to have two sets of ECG leads.8 Establishing and 
maintaining the quality of data from a trigger source is an important nursing 
responsibility. 
To establish maximal IABP support careful monitoring of the aortic pressure 
waveform is critical. IAB inflation and deflation must be synchronous with the 
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cardiac cycle. During systole (when blood is ejected from the left ventricle) the 
IAB should be deflated; during diastole (when there is no blood ejected from the 
left ventricle) the IAB should be inflated. The aortic pressure waveform  
represents systole and diastole. Systole occurs from the first point of positive 
pressure after the dicrotic notch (this immediately follows the lowest arterial 
pressure) to the highest arterial pressure and continues until the dicrotic notch 
(closure of the aortic valve). Diastole occurs from the advent of the dicrotic 
notch until the first point of positive pressure following this point. The IAB should 
be inflated on the dicrotic notch and deflated immediately prior to the first 
positive pressure following the dicrotic notch (Figure 1). If IAB inflation and 
deflation is not synchronised with the cardiac cycle optimal performance of 
IABP cannot occur. Late IAB deflation for example, would result in impedance 
of blood ejection from the left ventricle causing the heart to work harder and 
myocardial oxygen consumption to increase.10 Figure 2 presents waveform 
characteristics and physiologic effects of poorly timed IABP therapy. 
TAKE IN FIGURES 1 and 2 HERE. 
Determining adequate IABP timing involves careful analysis of the pressure 
waveform displayed on the IABP drive console and assessment of the patient’s 
haemodynamic response. Without synchrony, IAB inflation and deflation may 
increase myocardial oxygen demand and cardiac workload. The automatic 
timing functions on newer model IABP drive consoles facilitate timing 
optimisation even in the context of irregular rhythms such as atrial fibrillation. 
Given the variance in drive console functionality, an awareness of the timing 
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features of the machine and model in use is important. Despite technological 
advance, it remains the responsibility of the nurse to maintain a reliable trigger 
and ensure timing is regularly checked to maximise physiologic benefit to the 
patient. 
 
Observations  
To optimise the physiologic benefit of IABP, minimise IABP risks, and allow 
cardiac support to be individualised in response to variations in heart function, 
patient observation must be a continual process. Thorough knowledge, 
continual assessment and prompt intervention are essential in determining the 
best patient response. Bolooki11 advises haemodynamic variables requiring 
assessment to include: heart rate; arterial blood pressure; central venous 
pressure; pulmonary artery pressure; pulmonary capillary wedge pressure; and 
cardiac output. Clinical evaluation with ECG studies as well as chest x-ray may 
also be helpful in evaluating left ventricular function.11 However, in practice 
interventions used routinely in conjunction with IABP for data acquisition 
fluctuate significantly.1 To provide an accurate insight into the level of a patient’s 
cardiac function, a combination of clinical measurements and observations 
would appear necessary. Presenting this global picture of a patient’s cardiac 
function would generate the most effective approach to managing cardiac 
support.12  
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In Australasia, the primary routine intervention in the setting of IABP is a central 
venous catheter (used by 87% of Australasian units). Other interventions used 
to monitor the patient undergoing IABP are: intra-arterial lines (72% of units); 
pulmonary artery catheters (70% of units); transthoracic echocardiography 
(41% of units); transoesophageal echocardiography (39% of units); continuous 
cardiac output monitoring (7% of units); and saturated venous oxygenation (2% 
of units).1 Almost one third of Australasian practitioners choose not to use a 
pulmonary artery catheter – a previous mainstay for the monitoring of IABP.11 
This wide variability in monitoring practices between institutions likely reflect the 
extensive cardiovascular effects of IABP and potentially the need to standardise 
practices to allow for benchmarking.1 Irrespective of strategies used to monitor 
cardiac function, it is widely accepted that managing IABP encompasses many 
parameters, of which haemodynamic status is paramount.11-14 Nurses 
managing IABP must be able to participate in the continual assessment of 
haemodynamic status. 
Assessment of haemodynamic status begins with evaluation of the arterial 
pressure waveform. During IABP additional components exist in the pressure 
waveform resulting from balloon inflation and deflation and the consequent 
displacement of blood.15 Normally systole is the highest pressure reached 
during the cardiac cycle. However, during IABP, balloon inflation at the onset of 
diastole (which coincides with closure of the aortic valve) displaces blood in the 
aorta increasing the peak pressure – this increase in pressure is called diastolic 
augmentation.6, 9 The IAB remains inflated throughout diastole until immediately 
prior to systole. Upon IAB deflation the aorta becomes partially empty. Aortic 
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pressure will consequently drop lower than with an unassisted beat – the result 
is a dip in the waveform pattern called the assisted aortic end-diastolic pressure 
(which will result in an assisted systole).9 Where IABP support is offered with 
each cardiac beat (frequency of 1:1), assisted components of the pressure 
waveform reflect improvements in myocardial oxygen supply and reduce 
myocardial oxygen consumption by decreasing cardiac workload.5, 7 These 
assisted pressures should be routinely documented as evidence of IABP 
effectiveness.   
As with ECG and aortic pressure fluctuations, IABP assisted arterial pressures 
enable comparative analysis of cardiac function at different points in time. Any 
reduction in assist ratios of IAB inflation to cardiac contraction (1:2 or 1:4) 
requires careful assessment of the pressure waveform as unassisted 
contractions result in increased cardiac workload.16 If cardiac function is 
insufficient, the increasing workload owing to a reduction in frequency of 
inflation will result in reduced ejection of blood into the aorta. As a result there 
will be less blood in the aorta to be displaced during IAB inflation, which 
decreases diastolic augmentation.9 Alternatively when cardiac function 
improves and the systolic pressure achieved with myocardial contraction is 
higher, the difference between systolic pressure and augmented diastolic 
pressure will narrow. Interpretation of pressure waveforms is useful in 
understanding cardiac function and the support provided by IABP. However, a 
more comprehensive clinical picture regarding the degree of recovery or 
deterioration in cardiac function requires evaluation of other body systems.12  
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Cardiac function impacts widely on physiological processes throughout the 
body.4 Factors other than mean arterial pressure considered to reflect cardiac 
function have been noted to include: heart rate; lung function; lactate levels; 
renal function; and metabolic measures.1, 17 Trends in respiratory assessment 
data can reflect improvements in cardiac function. A key factor in the 
development of cardiogenic pulmonary oedema is poor systolic ejection from 
the left ventricle. Assisted end-diastolic pressure serves to improve ventricular 
ejection and it can be expected that this will lead to reduced pulmonary 
congestion. Improving oxygen requirements, adventitious breath sounds, air 
entry and respiratory rate can all be considered useful measures of reduced 
congestion reflecting improved cardiac function.12 Renal function may also be 
considered a good measure of cardiac function due to susceptibility of kidneys 
to low output states.18 Where cardiac output is augmented by IABP, 
improvements in renal function such as improved urine output may be 
observed. It is important for nurses to consider a multi-organ approach in 
monitoring the effects of IABP. 
 
Complications  
The importance of clinician exposure to IABP and experience with its use 
should not be underestimated.19 Mortality2 and complications20 have both been 
found to decrease in institutions with higher insertion rates. Mortality rates for 
patients requiring IABP are generally high and may increase if insertion is 
delayed.3, 20-22 However, mortality in the IABP cohort can largely be attributed to 
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the acuity of this patient group, underlying aetiology of heart failure and other 
co-morbidities.3 It is rare for complications of IABP itself to directly contribute to 
mortality. Analysis of 669 insertions at the Prince Charles Hospital between 
1994 and 2004 identified no mortality that could be directly attributed to IABP.20 
Recent literature suggests that overall IABP complications are low and 
decreasing overtime despite increasing application of IABP in clinical practice.19, 
23-27 However, the observations related to procedural outcomes relating to 
volume underscores the importance of considering development and 
assessment of nursing competencies and undertaking regular training to ensure 
competencies are maintained in units where IABP is used infrequently. 
Access site bleeding, limb ischaemia, and balloon failure (IAB rupture or 
entrapment) 19, 20, 23-25, 27 account for most reported complications.20, 28 Access 
site bleeding is the most common IABP complication. Bleeding is best managed 
with a gentle compressive bandage or primary suturing at the access site.28, 29 
Excessive pressure in attempting to control bleeding should be avoided as this 
potentially narrows the arterial lumen reducing peripheral blood flow and 
increasing the risk of limb ischemia. Limb ischaemia is most likely in patients 
with existing peripheral vascular disease, diabetes mellitus and those whose 
IAB insertion is sheathed.30 Sheaths contribute to vascular complications even 
in patients without peripheral vascular disease and sheathless insertion is 
clinically indicated in most patients.29 Recent technological advances leading to 
smaller catheter diameters may contribute to lower vascular complication 
rates.23 The impact of the new 7 French catheter may further contribute to 
reducing the risk of limb ischemia.31 Most cases of limb ischemia occur early 
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after balloon placement.23 In any case the risk of ischemia exists for all patients 
and regular assessment of peripheral circulation is therefore mandatory. 
Checking pedal pulse strength, with pedal colour, warmth, movement, and 
sensation frequently enables the early detection of complications. Vascular 
assessment should include both legs and arms due to the possibility of IAB 
migration and the consequent occlusion of the subclavian artery.28 Risk of 
ischemia is not isolated to limbs.  Severe ischemic outcomes such as paralysis 
have also been reported.28  Low urine output may also reflect distal migration of 
the balloon with subsequent occlusion of renal arteries. Lactate levels should 
also be monitored as a measure of tissue perfusion.17 Patients who experience 
limb ischemia as a result of IABP require device removal. Despite removing the 
IABP, surgical intervention is still required for many of these patients.29  
While repeated IAB inflation causes platelet damage, evidence suggests routine 
anticoagulation to be unnecessary.32 Despite the damage to platelets a clotting 
risk still exists if the IAB remains stationary for any period of time. In the event 
of a cardiac arrest the balloon mode should be set to flutter to avoid balloon 
stasis.33 In addition to platelet damage, the majority of IABP recipients 
experience a decrease in both red cell count and platelet count to the extent 
where IABP duration greater than 5 days may require blood transfusion.11 Full 
blood count should me monitored daily and close observation of the insertion 
site undertaken. Early detection and rapid intervention is the best means to 
reduce the incidence of serious progression of any IABP complication.32  
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Weaning intraaortic balloon counterpulsation 
Given the level of cardiac compromise necessitating IABP application, 
mechanical ventilation and pharmalogical assistance are frequently employed 
simultaneously to further assist the ailing heart. Maximal IABP assistance 
consists full IAB inflation at the onset of diastole following each cardiac 
contraction.34 As cardiac function improves support can be reduced. Withdrawal 
of IABP support, while progressive, is reliant on the degree of recovery in 
cardiac function and must be considered in the context of other support 
strategies. In practice the sequence for withdrawing cardiovascular supports 
such as mechanical ventilation, inotropes, or IABP is variable.1 Evidence 
supports the view that inotropic support should be minimised or withdrawn prior 
to the withdrawal of IABP support.11, 14, 15, 34-37 Drugs such as adrenaline 
increase the work of the heart. Therefore by reducing the level of pharmalogical 
support, myocardial oxygen demand can be reduced.37 Additionally, minimising 
drugs which support the heart allows an escalation of pharmacologic therapy 
following IABP withdrawal if the patient should deteriorate. Increasing 
pharmacologic support is an easier course of action than the reintroduction of 
IABP. Moving towards less aggressive drugs such dopamine or dobutamine 
ensures attempts to withdraw IABP are not made until there is evidence that 
cardiac function is improving.11, 14 A recent review of evidence concluded 
minimisation of pharmacological assistance should occur before considering 
any degree of withdrawal of IABP support.34 However, Australasian data reveals 
an inconsistency with only 26% of intensive care units clearly identifying 
pharmacological weaning as a strategy preceding reduction in IABP support 
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and a further 21% having no clear sequence for withdrawing support.1  Again 
this underscores the importance of evidence-based guidelines in promoting best 
practice and benchmarking outcomes.  
The withdrawal of IABP support may be either by frequency weaning or volume 
weaning. In the absence of direct evidence to support either option, both are 
offered as justifiable options for the withdrawal of IABP support. 11, 13, 14, 35, 36, 38 
The use of frequency weaning holds clinical appeal in Australasia with 61% of 
intensive care units surveyed identifying this as their sole strategy 1. Frequency 
reduction weaning involves the reduction in the total amount of assisted cardiac 
contractions from full assistance of 1:1 to partial assistance (IABP assistance 
less than every cardiac contraction). Initially this reduction is from 1:1 to 1:2 
(IABP assistance of every second cardiac contraction) and may progress to 
1:4.34 Frequency reduction exposes the heart to large variations in afterload, 
impacting upon the amount of work the heart is expected to perform13 and fails 
to increase cardiac vein flow.38 Additionally, examination of haemodynamic 
outcomes of weaning IABP in heart failure found frequency reduction to result in 
greater haemodynamic suppression when compared with volume weaning.39 
When considering the patient’s haemodynamic status, any reduction in IAB 
frequency could be the equivalent of complete IABP withdrawal. As such, the 
patient should be monitored carefully for cardiac decompensation.  
Volume weaning may be seen as a more physiological approach to weaning 
IABP. The reduction of IAB volume will gradually increase cardiac workload; it 
has also been demonstrated that larger catheter inflation volumes may further 
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augment cardiac output.40 Moreover, diastolic pressures augmented with IABP 
result in the redistribution of coronary blood flow toward ischaemic areas of the 
myocardium.16, 41 Considering arguments for frequency weaning and volume 
weaning, volume weaning would appear to be the method of choice when 
initiating the withdrawal of IABP support. Importantly, however, irrespective of 
the weaning strategy employed, having a clear plan for weaning is important. 
Intensive care units with a documented weaning policy demonstrate lower IABP 
reinsertion rates than those units without a weaning policy (p=0.06).1 This may 
reflect the value of carefully establishing a patient’s readiness to wean and 
carefully monitoring physiologic markers of cardiac function.14  
Considering patient response to IABP at all times is the key implication for 
nursing practice. The nurse must be constantly evaluating the patient response 
to decreasing IABP support with a view to identifying early cardiac 
decompensation.12 With significant variation in IABP weaning strategies it is 
important for nurses to understand all current approaches and their implications.  
Strategies to standardise processes  through evidence-based guidelines and 
consensus methods should be considered.  
 
Conclusion 
To achieve the best possible outcome for a patient managed with IABP nursing 
and medical staff require specialised skills. When caring for a patient managed 
with IABP the nurse must continually assess and measure the often subtle 
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changes in patient condition and this requires expert knowledge of the 
cardiovascular system, therapeutic effects of IABP and potential adverse 
events.  The heterogeneity of practice patterns across institutions underscores 
the importance of health professionals working together to collaboratively 
develop guidelines that promote best practice and allow benchmarking and 
monitoring of outcomes across centres. The lower mortality rates in high volume 
centres demonstrates the importance of ensuring maintenance of skills and 
competencies in IABP management. Developing and regularly assessing 
competencies through simulation techniques may be a strategy to ensure 
equitable outcomes for individuals receiving IABP.  
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